(Total Views: 584)
Posted On: 01/13/2022 10:58:41 AM
Post# of 148899
Maybe start with the doctor who has partnered with Cytodyn on breast cancer trials at MD Anderson. While it’s a different focus he may have recommendations and clearly he believes in the potential of Leronlimab already, which is the biggest hurdle. It’s probably 3-1/2 to 4 hours away from Dallas, so maybe it’s a drive worth taking if there’s someone down there more willing to help.
“ VANCOUVER, Washington, Oct. 07, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced a study for treating triple-negative breast cancer (TNBC) with leronlimab in a humanized TNBC xenograft model. This investigator-initiated study is being led by Jangsoon Lee, Ph.D., assistant professor of Breast Medical Oncology Research at The University of Texas MD Anderson Cancer Center.”
I wish you and your friend the best of luck.
“ VANCOUVER, Washington, Oct. 07, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced a study for treating triple-negative breast cancer (TNBC) with leronlimab in a humanized TNBC xenograft model. This investigator-initiated study is being led by Jangsoon Lee, Ph.D., assistant professor of Breast Medical Oncology Research at The University of Texas MD Anderson Cancer Center.”
I wish you and your friend the best of luck.
(5)
(0)Scroll down for more posts ▼
